Company Tagline
Stopping non-genetic cancer drug resistance as it emerges
Industry Category
Business Keywords
Company Description
TOLREMO therapeutics is a leading biotechnology research company dedicated to preventing non-genetic cancer drug resistance. By focusing on dismantling the earliest defenses against targeted therapies, TOLREMO therapeutics aims to significantly improve the response rates and durability of established treatments. The company's mission is driven by phenotypic insights, leading to the discovery of a pivotal mechanism governing critical transcriptional resistance pathways.
TOLREMO therapeutics' clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques, offering a promising approach to overcoming a universal challenge for current and future targeted therapies. With headquarters located at Hochbergerstrasse 60c, Basel, BS 4057, CH, TOLREMO therapeutics is committed to delivering lasting patient benefits through innovative drug discovery and development.
TOLREMO therapeutics is dedicated to advancing cancer treatment by stopping drug resistance as it emerges. By focusing on novel mechanisms and developing targeted inhibitors, TOLREMO therapeutics is poised to make a significant impact on the future of cancer therapy. We invite the management team at TOLREMO therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.
TOLREMO therapeutics est une entreprise de recherche biotechnologique de premier plan dédiée à la prévention de la résistance non génétique aux médicaments anticancéreux. En se concentrant sur le démantèlement des premières défenses contre les thérapies ciblées, TOLREMO therapeutics vise à améliorer de manière significative les taux de réponse et la durabilité des traitements établis. La mission de l'entreprise est guidée par des connaissances phénotypiques, menant à la découverte d'un mécanisme central régissant les voies critiques de la résistance transcriptionnelle.
Le composé clinique TT125-802 de TOLREMO therapeutics est un inhibiteur de petites molécules disponible par voie orale, conçu pour bloquer ces techniques de survie, offrant une approche prometteuse pour surmonter un défi universel pour les thérapies ciblées actuelles et futures. Avec son siège social situé à Hochbergerstrasse 60c, Bâle, BS 4057, CH, TOLREMO therapeutics s'engage à offrir des avantages durables aux patients grâce à la découverte et au développement de médicaments innovants.
TOLREMO therapeutics se consacre à faire progresser le traitement du cancer en stoppant la résistance aux médicaments dès son apparition. En se concentrant sur de nouveaux mécanismes et en développant des inhibiteurs ciblés, TOLREMO therapeutics est sur le point d'avoir un impact significatif sur l'avenir de la thérapie contre le cancer. Nous invitons l'équipe de direction de TOLREMO therapeutics à créer une vitrine d'entreprise et une liste de produits personnalisées et exclusives sur notre plateforme afin de mettre davantage en évidence leur travail révolutionnaire.
Key Personnel / Employees
Compare Companies Side by Side
Compare TOLREMO therapeutics with 3 companies in Biotechnology-Research
| Comparison Field |
TOLREMO therapeuticsMain Company |
Anthem Biosciences P...View Profile |
WuXi AppTecView Profile |
Cancer Research Hori...View Profile |
|---|---|---|---|---|
|
Founded Year
|
— | 2006 | 2000 | |
|
Company Size
|
— | 1,001-5,000 | 10,001+ | 1,001-5,000 |
|
City
|
Basel, BS | Bangalore, Karnataka | Shanghai, Shanghai | London, London |
|
Country
|
Switzerland | India | China | United Kingdom |
|
Skills & Keywords
Comparing with main company
|
11 Total Skills
Biotechnology
Drug Discovery
Cancer Research
Targeted Therapies
Drug Resistance
Pharmaceuticals
Oncology
Non-genetic Cancer Drug Resistance
Cancer Drug Resistance
Drug Development
Biotech
|
9 Total
2 Common
7 Unique
Match
18%
Common Skills:
Biotechnology
Pharmaceuticals
Unique Skills:
Agriculture Chemicals
Biology
Bio-Pharma
Chemistry
Contract Research Organization
CRO
+1
|
11 Total
11 Unique
Unique Skills:
API Development & Manufacturing
Bioanalytical
Biological Reagents
Biologics
Cell & Gene Therapy
Chemistry
+5
|
15 Total
1 Common
14 Unique
Match
9%
Common Skills:
Pharmaceuticals
Unique Skills:
Antibodies
Biologics
Biotherapeutics
Cancer research
Clinical Trials
Commercialisation
+8
|
4
Total Companies2000
Oldest Founded4
Countries40
Unique SkillsSimilar Companies
Other organizations in the same industry
BioSoc-DTU
Biotechnology-ResearchThe Biotechnology society of DTU aims to provide better research opportunities, conduct knowledge an...
Meta Biomed America
Biotechnology-ResearchBEYOND EXPECTATION
Ectin Research
Biotechnology-ResearchMedicine not ´miracle´ MFA-370: a novel therapy eliminating cancer tumors.
Alternative Company Names
This company is also known as